Loading clinical trials...

Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control

A Randomized Controlled Study on the Effectiveness, Safety and Adaptability of Double Helix Design Defocus Lens Spectacle Frames for Correction of Visual Acuity in Children and Adolescents, and Control of Myopia.

NCT05894382•Shanghai Eye Disease Prevention and Treatment Center

View on ClinicalTrials.gov

Summary

This study uses 1.585 double helix defocus lens PC lenses with a unique optical design that includes a globally coherent visible area and complementary left and right helices that can form clear images. In addition, the helical arrangement and reduced slit area can generate defocusing signals, inhibiting the development of myopia. Therefore, based on previous research, this study plans to evaluate the safety and effectiveness of 1.585 double helix defocus lens PC frame eyeglasses in controlling the progression of myopia in children and adolescents through a randomized controlled clinical trial.

Eligibility

Age

6 - 13 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Race: Chinese children and adolescents.
•2. Age 6-13 years, gender unrestricted.
•3. Cycloplegic refraction SER: -0.75DS\~-5.0DS in both eyes.
•4. Best corrected visual acuity of both eyes reaches 1.0 (0.00 logMAR 6/6).
•5. Refractive astigmatism and astigmatism are no more than 1.5D.
•6. During the study period, willing to wear glasses provided by the researcher only (\>10 hours) and without additional interventions.
•7. Willing to be randomly assigned.
•8. Able to sign an informed consent form with the accompaniment and understanding of parents or guardians.

Exclusion Criteria

•1. Allergic or intolerant to medications used for ciliary muscle paralysis.
•2. Received any nearsightedness treatment such as atropine, rigid gas permeable contact lens, bifocal/progressive lens, red light therapy, or acupuncture within 30 days before the study.
•3. Received defocus lenses for nearsightedness treatment in the past.
•4. Diagnosed with any eye disease other than nearsightedness, including strabismus (esotropia greater than 8 prism diopters or exotropia greater than 12 prism diopters), corneal diseases, conjunctival or eyelid damage or other conditions (such as keratoconus, herpes simplex keratitis, etc.).
•5. History of eye surgery (including strabismus correction surgery).
•6. Eye or systemic diseases that might be associated with nearsightedness or its progression, such as Marfan syndrome, retinopathy of prematurity, diabetes, etc.
•7. Anatomical or dermatological factors that may interfere with the wearing of spectacle frames.
•8. Other reasons that the researcher deems inappropriate for the participant to be included in the study, such as excessively high expectations for the effectiveness of defocus lenses, or plans to use other nearsightedness intervention strategies simultaneously with the study.

Locations (1)

Xiangui He

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

June 3, 2023

Primary Completion Date

August 31, 2026

Completion Date

December 31, 2026

Last Updated

December 8, 2025

Enrollment

236

ESTIMATED participants

Conditions

Myopia, Progressive

Interventions

Double Helix Design Defocus Lens Spectacle (RACE)

DEVICE

single-vision spetacle lens

DEVICE

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

NCT06579287

Myopia, Progressive

View study

ACTIVE_NOT_RECRUITINGPHASE2/PHASE3

Low-dose Atropine for Myopia Control in Children

NCT03865160

Myopia, Progressive

View study

ACTIVE_NOT_RECRUITINGNA

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression

NCT03818880

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control

Inclusion Criteria

Exclusion Criteria

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

Low-dose Atropine for Myopia Control in Children

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression

Study of OT-101 in Treating Myopia

Myopia Prevention Through Monitoring and Motivating Outdoor Activities With Smartwatches

Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop